Aptar Pharma Granted Exclusive License Option by Pharmaxis to Develop and Promote High Payload Dry Powder Inhaler 18 Aug 2021 Press Packagin… Agreement gives Aptar Pharma an exclusive 12-month option to acquire worldwide rights to Pharmaxis’ proprietary “Orbital” technology, which delivers large payloads of drug in a convenient, easy-to-use format Read more about Aptar Pharma Granted Exclusive License Option by Pharmaxis to Develop and Promote High Payload Dry Powder InhalerLog in or register to post comments Tags oxidase inhibitors High Payload Dry Powder Inhaler respiratory products
